What is HC Wainwright’s Estimate for VNDA Q4 Earnings?

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) – Research analysts at HC Wainwright lifted their Q4 2026 EPS estimates for shares of Vanda Pharmaceuticals in a research note issued on Monday, January 5th. HC Wainwright analyst R. Selvaraju now expects that the biopharmaceutical company will post earnings of $0.06 per share for the quarter, up from their prior estimate of $0.03. HC Wainwright currently has a “Buy” rating and a $22.00 price target on the stock. The consensus estimate for Vanda Pharmaceuticals’ current full-year earnings is ($1.12) per share.

A number of other brokerages have also issued reports on VNDA. UBS Group reaffirmed a “buy” rating on shares of Vanda Pharmaceuticals in a report on Monday. B. Riley upped their target price on shares of Vanda Pharmaceuticals from $11.00 to $14.00 and gave the stock a “buy” rating in a research report on Wednesday, December 31st. Cantor Fitzgerald reiterated an “overweight” rating on shares of Vanda Pharmaceuticals in a report on Wednesday, December 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research note on Wednesday, October 8th. Finally, Jefferies Financial Group increased their price objective on shares of Vanda Pharmaceuticals from $5.00 to $7.50 and gave the company a “hold” rating in a report on Wednesday, December 31st. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Vanda Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $13.63.

Vanda Pharmaceuticals Stock Up 5.0%

Shares of VNDA opened at $8.54 on Tuesday. The business’s 50 day moving average is $5.87 and its 200 day moving average is $5.17. The company has a current ratio of 3.12, a quick ratio of 3.10 and a debt-to-equity ratio of 0.01. Vanda Pharmaceuticals has a 12-month low of $3.81 and a 12-month high of $9.60. The company has a market capitalization of $504.71 million, a PE ratio of -6.01 and a beta of 0.60.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings results on Wednesday, October 29th. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.07). Vanda Pharmaceuticals had a negative return on equity of 16.82% and a negative net margin of 39.70%.The business had revenue of $56.26 million during the quarter, compared to analysts’ expectations of $58.73 million.

Hedge Funds Weigh In On Vanda Pharmaceuticals

Several institutional investors have recently bought and sold shares of VNDA. JPMorgan Chase & Co. grew its stake in shares of Vanda Pharmaceuticals by 16.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 199,893 shares of the biopharmaceutical company’s stock worth $997,000 after buying an additional 28,238 shares in the last quarter. Krensavage Asset Management LLC raised its position in shares of Vanda Pharmaceuticals by 15.2% during the 3rd quarter. Krensavage Asset Management LLC now owns 1,180,388 shares of the biopharmaceutical company’s stock valued at $5,890,000 after buying an additional 155,505 shares in the last quarter. PharVision Advisers LLC bought a new position in shares of Vanda Pharmaceuticals in the 3rd quarter valued at about $285,000. Quarry LP purchased a new position in Vanda Pharmaceuticals in the third quarter worth about $53,000. Finally, Qube Research & Technologies Ltd purchased a new position in Vanda Pharmaceuticals in the third quarter worth about $894,000. Institutional investors own 88.14% of the company’s stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.